ArticleDrug discovery today. Disease models2010
Experimental Models of Membranous Nephropathy.
Article in Drug discovery today. Disease models, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Deep Learning Enables Automated Segmentation and Quantification of Ultrastructure from Transmission Electron Microscopy Images.bioRxiv : the preprint server for biology · 2026Article
- A rat model of Immunologic and hypertensive kidney injury.Scientific reports · 2026Article
- Dampness syndrome aggravates T helper 17/regulatory T imbalance to promote renal injury in rats with experimental membranous nephropathy.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Astragaloside IV relieves passive heymann nephritis and podocyte injury by suppressing the TRAF6/NF-κb axis.Renal failure · 2024Article
- Apical tubular complement activation and the loss of kidney function in proteinuric kidney diseases.Clinical kidney journal · 2024Review
- C3aR-initiated signaling is a critical mechanism of podocyte injury in membranous nephropathy.JCI insight · 2024Article
- Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases.Frontiers in immunology · 2024Article
- Downregulation of TRPC6 regulates ERK1/2 to prevent sublytic C5b‑9 complement complex‑induced podocyte injury through activating autophagy.Experimental and therapeutic medicine · 2023Article
- Combination therapy with DHA and BMSCs suppressed podocyte injury and attenuated renal fibrosis by modulating the TGF-Renal failure · 2023Article
- Currently Used Methods to Evaluate the Efficacy of Therapeutic Drugs and Kidney Safety.Biomolecules · 2023Review
- Article
- Crocin improves the renal autophagy in rat experimental membranous nephropathy via regulating the SIRT1/Nrf2/HO-1 signaling pathway.Renal failure · 2023Article
- Article
- Glomerulus-on-a-Chip: Current Insights and Future Potential Towards Recapitulating Selectively Permeable Filtration Systems.International journal of nephrology and renovascular disease · 2022Review
- Jianpi Qushi Heluo Formula alleviates renal damages in Passive Hemann nephritis in rats by upregulating Parkin-mediated mitochondrial autophagy.Scientific reports · 2021Article
- Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury.Antioxidants (Basel, Switzerland) · 2021Review
- Membranous nephropathy in a patient with coronavirus disease 2019 (COVID-19): A case report.Clinical nephrology. Case studies · 2021Article
- Advances of the experimental models of idiopathic membranous nephropathy (Review).Molecular medicine reports · 2020Review
- Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Kidney disease models: tools to identify mechanisms and potential therapeutic targets.Zoological research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Membranous nephropathy (MN) is one of the commonest glomerular diseases, typically presenting in older males with nephrotic syndrome. The development and characterization of animal models of MN, in particular, the passive Heymann nephritis model (PHN), has greatly advanced our understanding of this disease. In this review we discuss the different animal models of human MN that are available, with an emphasis on the PHN model, including technical issues, the typical disease course and its application to human disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.